Cover Image
市場調查報告書

HIV:流行病學、患者為基礎的市場預測,治療流程,及上市藥、開發平台藥物分析

HIV: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365201
出版日期 內容資訊 英文 455 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
HIV:流行病學、患者為基礎的市場預測,治療流程,及上市藥、開發平台藥物分析 HIV: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年01月01日 內容資訊: 英文 455 Pages
簡介

儘管預測了暢銷首發藥的學名藥銷售,HIV盛行率的上升及高級STR (1日1次1片藥物)的持續性採用,預計從2015年到2024年持續促進市場成長。

本報告以HIV的已上市及臨床實驗中 (開發平台上)的治療藥為焦點,提供在預測期間內預計支撐HIV市場成長的首發藥,Triumeq 及 Tivicay 銷售的成功程度和治療流程的現在地位,確診的患者現在治療中、接受抗逆轉錄病毒療法的患者的比例,及最近的美國、EU的治療指南的修訂,對新確診患者的處方模式的影響等相關分析。

預測:HIV

  • 摘要整理
  • 市場概要、趨勢
  • 市場定義、調查手法
  • 首發藥的預測
  • Atripla
  • Complera
  • D/C/F/TAF
  • Epzicom
  • fostemsavir
  • F/TAF
  • Genvoya
  • Isentress
  • Prezista franchise
  • Reyataz franchise
  • R/F/TAF
  • Stribild
  • Tivicay
  • Triumeq
  • Truvada
  • 1次調查手法

治療:HIV

  • 摘要整理
  • 1次調查手法
  • 疾病定義、診斷
  • 患者區分
  • 各國治療系統
  • 目前治療選擇
  • HIV的未滿足需求
  • 非專利的影響

流行病學

  • 摘要整理
  • 來源、手法
  • 預測
  • 流行病學者的考察
  • 優勢和弱點

上市藥:HIV

  • 摘要整理
  • 產品概要

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC5240

Despite the anticipated launch of generics of blockbuster brands, an increase in HIV prevalence and continued uptake of premium single-tablet regimens (STRs) will drive continued market growth during 2015-24.

This report addresses the following questions:

  • Which brands will drive further growth in the HIV market during 2015-24, and why?
  • How successful have Triumeq's and Tivicay's launches been and where are they currently positioned in the treatment algorithm?
  • What are physicians' views on the breaking up of fixed-dose combinations to prescribe cheaper separate generic components?
  • What percentage of diagnosed patients are currently under medical care and receiving antiretroviral therapy?
  • How will recent updates to US and EU treatment guidelines affect prescribing patterns in newly diagnosed patients?

TABLE OF CONTENTS

FORECAST: HIV

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Market Definition and Methodology
  • 4. Brand Forecasts
  • 5. Atripla
  • 6. Complera
  • 7. D/C/F/TAF
  • 8. Epzicom
  • 9. fostemsavir
  • 10. F/TAF
  • 11. Genvoya
  • 12. Isentress
  • 13. Prezista franchise
  • 14. Reyataz franchise
  • 15. R/F/TAF
  • 16. Stribild
  • 17. Tivicay
  • 18. Triumeq
  • 19. Truvada
  • 20. Primary Research Methodology

TREATMENT: HIV

  • 21. Executive Summary
  • 22. Primary Research Methodology
  • 23. Disease Definition and Diagnosis
  • 24. Patient Segmentation
  • 25. Country Treatment Trees
  • 26. Current Treatment Options
  • 27. Prescribing Trends
  • 28. Unmet Needs in HIV
  • 29. Impact of Generics

EPIDEMIOLOGY: HIV

  • 30. Executive Summary
  • 31. Sources and Methodology
  • 32. Forecast
  • 33. Epidemiologist Insight
  • 34. Strengths and Limitations

MARKETED DRUGS: HIV

  • 35. Executive Summary
  • 36. Product Overview
Back to Top